Traws Pharma Inc reports results for the quarter ended June 30 - Earnings Summary

Traws Pharma

14/08/2026 22:08

Traws Pharma Inc TRAW.OQ reported a quarterly adjusted loss of 25 cents​​ per share for the quarter ended June 30.  The mean expectation of two analysts for the quarter was for a loss of 34 cents per share. Wall Street expected results to range from -45 cents to -22 cents per share.
Reported revenue was zero​; analysts expected zero. 
Traws Pharma Inc's reported EPS for the quarter was a loss of 16 cents​.
The company reported a quarterly loss of $2.61 million.
Traws Pharma Inc shares had fallen by 28.9% this quarter and lost 46.9% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 56.7% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is  "buy."
Wall Street's median 12-month price target for Traws Pharma Inc is $1.00, about 40% above its last closing price of $0.60
This summary was machine generated from LSEG data August 14 at 09:08 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.34
-0.25
Beat
Mar. 31 2026 
-0.74
-0.53
Beat
Dec. 31 2025 
-1.22
0.63
Beat